Dealmaker Breaks Down The Daiichi Sankyo-Ranbaxy Deal: PharmAsia News Spotlight

Japan health care reforms enacted in April aimed at increasing the use of generics helped set the stage for the watershed deal between Daiichi Sankyo and Ranbaxy, and will have major implications for Indian generics companies, according to Mehta Partners, the Indian firm that brokered the deal on behalf of Daiichi